Morningstar‘s Stock Analysis 142760
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile 142760
BL Corp, formerly Bioleaders Corp engages in the biomedicine and biomaterial business in South Korea. It develops cervical intraepithelial dysplasia treatment which is in phase 3 clinical-stage; cervical cancer treatment which is in phase 2b clinical stage; and non-clinical vaccine adjuvant and treatment for muscular dystrophy.
Yongin-Si, 305-500, Korea, Republic of